First National Bank of Omaha Makes New Investment in Enovis Corporation $ENOV
First National Bank of Omaha has made a new investment in Enovis Corporation, purchasing 60,369 shares valued at approximately $1.25 million during the second quarter. This move makes First National Bank of Omaha an approximate 0.10% owner of Enovis. Other institutional investors like Dimensional Fund Advisors LP and Rubric Capital Management LP also adjusted their positions in the company, highlighting significant institutional interest.
What Enovis (ENOV)'s Narrowing Losses And Reaffirmed 2026 Outlook Means For Shareholders
Enovis Corporation reported Q2 2026 results with reduced net losses and reaffirmed its 2026 revenue guidance of US$2.31 billion to US$2.37 billion, including 4–6% organic growth. This indicates management's confidence in the company's trajectory, despite ongoing losses. The investment narrative emphasizes consistent profitability from its medtech portfolio, with margin improvement and successful integration of acquisitions being key near-term catalysts and risks.
What Enovis (ENOV)'s Narrowing Losses And Reaffirmed 2026 Outlook Means For Shareholders
Enovis Corporation reported narrowing losses and reaffirmed its 2026 revenue guidance of US$2.31 billion to US$2.37 billion, including 4–6% organic growth. This supports the investment narrative that execution on margin improvement is a key near-term catalyst, despite ongoing integration complexities and historical losses. The article emphasizes that while losses are improving, the company's long-term profitability and fair value will depend on how effectively guided growth translates into better margins.
Enovis Corporation (NYSE:ENOV) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Enovis Corporation (NYSE:ENOV) has received a "Moderate Buy" consensus rating from analysts, with eight out of ten recommending a buy, one a hold, and one a sell. The average 12-month price target is $41.29, significantly higher than its current share price of $24.79. Recent quarterly results surpassed expectations, and insiders have purchased additional shares, indicating confidence in the company.
Canaccord Genuity Group Lowers Enovis (NYSE:ENOV) Price Target to $45.00
Canaccord Genuity Group has lowered its price target for Enovis (NYSE:ENOV) to $45.00 from $50.00, while reiterating a "buy" rating, indicating a potential 72.53% upside. This adjustment follows other analyst updates, though the stock maintains an overall "Moderate Buy" rating with an average target of $41.29. Enovis recently surpassed quarterly earnings expectations and provided strong fiscal 2026 EPS guidance, with significant institutional ownership and recent insider share purchases highlighting investor interest.
Rubric Capital discloses 3.9M-share Enovis (ENOV) position in Schedule 13G
Rubric Capital Management LP and David Rosen have jointly filed a Schedule 13G, disclosing beneficial ownership of 3,900,000 shares of Enovis Corporation (ENOV) common stock. This position represents 6.78% of the company's outstanding shares, based on 57,562,603 shares as of May 1, 2026. Both parties report shared voting and dispositive power over these shares, which are held by investment funds advised by Rubric Capital, including Rubric Capital Master Fund LP.
Enovis Corporation (ENOV) Stock Forecasts
Argus has lowered its target price for Enovis Corporation (ENOV) to $23.00. Enovis is a medical technology company providing devices and services for patient care, from injury prevention to rehabilitation. The current price of ENOV stock is $26.25.
Can Enovis (ENOV) Narrowing Losses Without Strong Sales Growth Sustain Its Long-Term Strategy?
Enovis Corporation (ENOV) reported Q2 2026 sales of US$582.78 million, a modest increase year-over-year, and significantly reduced its net loss to US$1.19 million from US$36.74 million. The company reaffirmed its 2026 revenue guidance of US$2.31 billion to US$2.37 billion, indicating management's confidence despite only incremental sales growth. The article explores whether Enovis's strategy of narrowing losses without robust sales growth, primarily through acquisitions in medtech and orthopedics, is sustainable for long-term profitability.
Can Enovis (ENOV) Narrowing Losses Without Strong Sales Growth Sustain Its Long-Term Strategy?
Enovis (ENOV) reported modestly higher sales in Q2 2026, reaching US$582.78 million, while significantly reducing its net loss to US$1.19 million. The company reaffirmed its 2026 revenue outlook of US$2.31 billion to US$2.37 billion, indicating confidence despite incremental sales growth. The article discusses whether Enovis's strategy of narrowing losses without substantial sales growth is sustainable, given its history of acquisitions, concentration in orthopedics, and potential delays in technology launches.
Enovis Corporation (ENOV) Stock Forecasts
Argus has raised its target price for Enovis Corporation (ENOV) to $32.00, with the stock currently trading at $25.13. Enovis Corp is a medical technology company specializing in devices and services for patient care, from injury prevention to rehabilitation. Full details are available in an exclusive report for Yahoo Finance Silver subscribers.
Enovis (ENOV) Reaffirmed Guidance And Improved Margins, Is The Stock Still Undervalued?
Enovis (ENOV) reaffirmed its full-year 2026 revenue guidance and reported improved Q2 results, including organic growth and margin improvement, leading to a smaller net loss. Despite recent stock performance showing some momentum, the company is still considered undervalued by analysts, trading below the fair value estimate of $42.30. The article highlights both growth opportunities in the orthopedic market and integration risks from acquisitions, advising investors to review the underlying data.
Should You Investigate Enovis Corporation (NYSE:ENOV) At US$26.61?
This article evaluates Enovis Corporation's (NYSE:ENOV) stock at its current price of US$26.61. It will likely delve into financial metrics, analyst sentiment, and market conditions to determine if it's an attractive investment opportunity.
Enovis Q2 Earnings Call Highlights
Enovis reported Q2 2026 sales of $583 million, a 3% increase, driven by growth in its Reconstruction business despite challenges from the Middle East conflict and inflation. The company reaffirmed its full-year guidance, expecting sales growth to accelerate in Q4 with new product launches. Despite cost pressures, Enovis saw improved margins and positive free cash flow, and aims to further reduce leverage and expand margins in the long term.
Evercore Maintains Enovis Corp(ENOV.US) With Buy Rating, Maintains Target Price $32
Evercore has reiterated its Buy rating on Enovis Corp (ENOV.US) and maintained its target price at $32. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Enovis Q2 Earnings Call Highlights
Enovis reported Q2 2026 sales of $583 million, up 3% reported and 5% organically, driven by strong growth in its Reconstruction business. The company reaffirmed its full-year guidance, expecting sales growth to accelerate in Q4 due to new product launches and market improvements, despite headwinds from Middle East disruptions and inflation. Enovis also saw improved margins and positive free cash flow in the first half, while reducing leverage.
Enovis (ENOV) Stock Eyes Margin Gains as Free Cash Flow Improves
Enovis (ENOV) stock saw a modest 1.1% increase despite reporting significant improvements in its Q2 financials, including a narrowed net loss, improved gross and EBITDA margins, and positive free cash flow of US$31 million. The company's future prospects hinge on translating operational progress into sustained free cash flow and margin strength, though skeptics highlight execution risks and inflationary pressures. Investors are focusing on how Enovis's current financial profile aligns with its long-term profitability goals and debt reduction efforts.
Enovis Corporation Stock 12‑Month Price Target Cut to $41.25, Implies 37% Upside
The average 12-month price target for Enovis Corporation (ENOV) stock has been lowered from $41.58 to $41.25 by analysts, despite this reduction, the new target still suggests a potential upside of approximately 37% based on the August 5th closing price. The consensus rating for ENOV remains "Buy" among 13 analysts, with 12 recommending a Buy and 1 a Hold.
Enovis (ENOV) Beats Q2 Earnings and Revenue Estimates
Enovis (ENOV) reported Q2 earnings of $0.9 per share, exceeding the Zacks Consensus Estimate of $0.83, and revenues of $582.78 million, also surpassing estimates. The company has consistently beaten EPS estimates over the last four quarters and revenue estimates three out of the last four quarters. Despite outperforming the market year-to-date, Enovis currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market.
Enovis Q2 2026 slides show margin gains despite stock decline
Enovis Corporation reported strong second-quarter 2026 results, showing 5% organic growth, significant margin expansion, and improved free cash flow. Despite beating earnings expectations and reaffirming full-year guidance, the stock declined 8.4%, reflecting investor concerns about near-term headwinds and the absence of raised guidance. The company emphasized continued execution, new product launches like the ARVIS surgical system, and a focus on profitability improvement, targeting high-teens EBITDA margins.
Enovis Corp (ENOV) (Q2 2026) Earnings Call Highlights: Strong Innovation Drives 5% Organic ...
Enovis Corp (ENOV) reported strong Q2 2026 earnings with 5% organic growth, driven by innovation in hips/knees and shoulders, leading to improved gross margins and positive free cash flow. Despite facing inflationary pressures and softer international markets due to geopolitical conflicts and Western European market conditions, the company reaffirmed its 2026 guidance, expecting accelerated growth in Q4 from new product launches. Management expressed confidence in continued margin expansion and cash flow improvement in 2027, attributing success to strategic product rollouts and operational efficiencies.
Enovis Backs 2026 Guidance >ENOV
Enovis is reaffirming its financial guidance for 2026. The company anticipates achieving $2.5 billion in revenue and an adjusted EBITDA margin of 23% by that year. This reiteration suggests confidence in their ongoing business strategies and growth trajectory.
Why Enovis (ENOV) Shares Are Sliding Today
Enovis Corporation's shares fell 12.8% after reporting second-quarter earnings, despite revenue and adjusted earnings surpassing Wall Street expectations. The decline was attributed to a weaker full-year earnings per share outlook and a significant contraction in the company's adjusted operating margin, which fell 6.7 percentage points year-on-year to 4.5%. This profitability concern, coupled with broader industry fears about insurance plan changes impacting U.S. procedure growth, led to the negative investor reaction.
Enovis CORP 2026: Revenue $582.78M, EPS ($0.02) — 10-Q Summary
Enovis CORP (ENOV) reported its 2026 Q3 results, showing a revenue of $582.78M, a 3.2% increase year-over-year. The company significantly reduced its net loss to ($1.19M) from ($36.74M) in the prior-year quarter, with diluted EPS improving to ($0.02) from ($0.64). This performance was driven by volume gains in Recon and P&R segments, gross margin expansion, and moderating integration costs from the Lima acquisition.
Press Release: Enovis Announces Second Quarter 2026 Results
This press release from Enovis announces their second-quarter 2026 financial results. The company details its performance for the quarter, providing key financial metrics and highlights. This information is crucial for investors and stakeholders to understand the company's recent operational and financial standing.
Enovis (NYSE:ENOV) Posts Q2 CY2026 Sales In Line With Estimates
Enovis (NYSE:ENOV) reported Q2 CY2026 sales of $582.8 million, meeting Wall Street estimates, with non-GAAP profit exceeding consensus by 6.3% at $0.90 per share. The company reaffirmed its full-year revenue and Adjusted EPS guidance. While long-term revenue growth has been a challenge, recent two-year growth and improved operating margins show some positive signs, though share dilution has impacted per-share earnings.
Enovis 2Q Adjusted EBITDA $104M >ENOV
Enovis announced its second-quarter adjusted EBITDA reached $104 million. This financial update provides key performance indicators for the company during the recent quarter.
Enovis posts Q2 2026 revenue $583M, adjusted EBITDA $104M and reaffirmed full-year guidance
Enovis reported Q2 2026 net sales of $582.8 million and adjusted EBITDA of $104.3 million, showing growth in both reported and organic sales. The company reaffirmed its full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EPS, and free cash flow conversion. Management highlighted improved commercial execution, product innovation, and a reshaped portfolio, while maintaining a cautious outlook for macro dynamics in the second half of 2026.
Enovis Q2 2026 earnings: Reconstructive growth lifts margins
Enovis (NYSE: ENOV) reported strong Q2 2026 results, with net sales up 3.2% to $582.8 million and GAAP diluted EPS improving significantly. Reconstructive was the primary sales driver, and the company achieved improved operating leverage, leading to a GAAP operating profit. Enovis reaffirmed its full-year 2026 guidance, expecting continued growth despite a potentially dynamic macroeconomic environment.
Enovis Announces Second Quarter 2026 Results
Enovis Corporation announced its financial results for the second quarter ended July 3, 2026, reporting sales growth of 3% on a reported basis and 5% organically, reaching $583 million. The company experienced an 8% reported growth in Reconstructive sales, alongside a net loss of $1 million. Enovis reaffirmed its full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EPS, and free cash flow conversion.
Form 8K Enovis Corp For: 6 August By Investing.com
This article reports on the filing of Form 8K by Enovis Corp on August 6th. The brief news item includes standard financial market data, indices, commodities, and various stock performances. It also highlights popular news articles from Investing.com and Reuters on topics ranging from gold prices and SpaceX to Tesla's manufacturing plans and geopolitical warnings.
Earnings Flash (ENOV) Enovis Corporation Reports Q2 Revenue $582.8M, vs. FactSet Est of $581.8M
Enovis Corporation (ENOV) announced its Q2 revenue of $582.8 million, surpassing FactSet's estimate of $581.8 million. The company also reported Q2 adjusted EPS of $0.90 per share, exceeding the FactSet estimate of $0.85 per share, and reaffirmed its earnings guidance for the year 2026.
Enovis earnings up next as analysts eye Lima deal, cash flow
Enovis Corp. is preparing to report its second-quarter earnings, with analysts focusing on the company's Lima integration and cash flow generation amidst tempered expectations. Despite a sequential decline forecasted from Q1, Wall Street maintains a bullish outlook with a consensus "buy" rating. Investors will be monitoring margin performance and the company's ability to convert market opportunities into sustained financial performance, especially given its high gross profit margin and heavy investment in innovation.
Enovis (ENOV) Reports Q2: Everything You Need To Know Ahead Of Earnings
Enovis Corporation (ENOV) is set to report its Q2 earnings this Thursday. The medical technology company exceeded revenue expectations last quarter with $589.2 million, and analysts anticipate a 3.1% year-over-year revenue growth for the upcoming report. Despite some past misses, Enovis's stock is up 18.5% over the last month, outperforming its segment peers, and holds an average analyst price target of $41.58 against a current share price of $30.68.
Enovis (ENOV) Reports Q2: Everything You Need To Know Ahead Of Earnings
Enovis (ENOV) is set to report its Q2 earnings this Thursday morning. The medical technology company previously beat revenue expectations and analysts are anticipating a 3.1% year-on-year revenue growth for the upcoming quarter. Its stock has outperformed peers in the medical devices & supplies - specialty segment, showing an 18.5% increase over the last month.
Are Enovis’ (ENOV) Sales Declines Quietly Rewriting Its Core Growth and Capital Allocation Story?
Enovis (ENOV) is experiencing ongoing annual sales declines and weakening returns on capital, raising concerns about the effectiveness of its growth initiatives and capital deployment. The company's Q1 2026 results showed narrowed net losses but continued sales pressure, leading analysts to question the durability of any improvement and the impact on its investment narrative. Investors are encouraged to conduct their own research, with some analyst estimates suggesting a potential upside for the stock.
ENOV|Enovis Corp|Price:29.150|Chg%:-0.140
This article provides a comprehensive stock analysis of Enovis Corp (ENOV), highlighting its strong fundamentals, high growth potential, and fair valuation within the Healthcare Equipment & Supplies industry. Despite institutional selling and technical indicators not fully supporting the current trend, analysts rate it as a "Buy" with a significant upside. The report details Enovis's business segments, strengths like high revenue and profit growth, and risks such as being overvalued and institutional selling.
Enovis Corp (ENOV) Institutional Confidence
This article analyzes the institutional confidence in Enovis Corp (ENOV), noting its current score of 10.00, ranking 1st in the Healthcare Equipment & Supplies industry. Institutional shareholding proportion is 119.81%, a decrease of 4.63% quarter-over-quarter. The largest institutional shareholder is ETHSX, which significantly increased its holdings.
Are Enovis’ (ENOV) Sales Declines Quietly Rewriting Its Core Growth and Capital Allocation Story?
Enovis (ENOV) has experienced ongoing annual sales declines and weakening returns on capital, raising concerns about its growth initiatives and operational effectiveness. Despite a narrowed net loss in Q1 2026, persistent sales pressure and impaired returns suggest deeper issues with its business model and capital deployment. This situation challenges the previously optimistic investment narrative and risk profile, prompting investors to scrutinize whether growth initiatives are truly creating shareholder value.
Are Enovis’ (ENOV) Sales Declines Quietly Rewriting Its Core Growth and Capital Allocation Story?
Enovis (ENOV) is experiencing ongoing annual sales declines and weakening returns on capital, raising questions about the effectiveness of its growth initiatives and capital deployment. While Q1 2026 showed a narrowed net loss, persistent sales pressure and impaired returns suggest deeper operational challenges. These issues could alter the company's investment narrative and risk profile, with analysts projecting varied outcomes for its revenue and earnings by 2029.
Enovis Number of Employees 2026 | Employee Count & Headcount Data
Enovis Corp. (ENOV) had approximately 7,891 employees worldwide as of March 2026, marking an 8.2% growth from 2023. The company is actively hiring with 487 job postings in 2026, a 20.9% increase from 2025. While the workforce grew overall since 2023, it saw a slight year-over-year decline of 0.1% in 2026, and employee sentiment is reported as negative and declining.
ENOV|Enovis Corp|Price:30.255|Chg%:+0.735
Enovis Corp (ENOV), a medical technology company, is currently trading at $29.310 with a market cap of $1.68 billion. Analysts rate the stock as "Buy" with a target price of $41.917, suggesting a 48.38% upside. Despite strong stock performance and fundamentals over the last month, technical indicators suggest sideways trading, suitable for range-bound swing trading.
UBS Adjusts Price Target on Enovis to $51 From $50, Maintains Buy Rating
UBS has increased its price target for Enovis (NYSE: ENOV) to $51, up from $50, while reaffirming its Buy rating on the stock. This adjustment reflects a continued positive outlook from the firm regarding Enovis's financial prospects and market position.
BlackRock (NYSE: BLK) discloses 9.18M-share, 15.9% holding in Enovis (ENOV)
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 9,181,052 shares in Enovis Corporation (ENOV), representing 15.9% of the company's common stock. BlackRock holds sole voting power over 9,087,287 shares and sole dispositive power over all 9,181,052 shares. The filing also notes that the iShares Core S&P Small-Cap ETF, associated with BlackRock, holds more than a five percent interest in Enovis common stock.
Enovis Market Sentiment
The article provides an overview of market sentiment for Enovis (ENOV), including analyst consensus, short interest, and recent analyst actions. It highlights a "Buy" consensus from 17 analysts with an average price target of $52, and notes a 19.7% rising short float, indicating bearish sentiment. The report details numerous analyst ratings, price target changes, and actions from firms like UBS, BMO Capital, and Evercore ISI Group.
ENOV|Enovis Corp|Price:27.030|Chg%:+0.990
Enovis Corp is a medical technology company specializing in reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through two segments, Prevention & Recovery and Reconstructive, offering a range of medical devices and solutions. Key executives, shareholding information, institutional holdings, and revenue breakdown are provided for the company.
Enovis Corporation (ENOV) Stock Analysis: A 51.74% Upside Potential with Strong Buy Ratings
Enovis Corporation (ENOV), a medical device company, shows a significant upside potential of 51.74% with strong buy ratings from analysts. Despite challenges in profitability and a negative EPS, the company is strategically positioned for growth with a robust free cash flow and innovative product offerings in the healthcare sector. Analysts have a consensus target price of $40.73, indicating optimism regarding its future appreciation.
Enovis (ENOV) 43rd Annual J.P. Morgan Healthcare Conference 2025 Summary
Enovis's 2025 J.P. Morgan Healthcare Conference summary highlights the company's strategic shift to a focused MedTech entity, driven by organic growth, acquisitions like Lima and Mathys, and operational excellence through its EGX system. The company reported successful integration of Lima, leading to revenue and EBITDA margin improvements, and is poised for higher organic growth and continued innovation with over 30 new product launches planned. Significant growth drivers include its Recon business focused on high-growth extremities and advanced technologies
Is Enovis (ENOV) Undervalued On Its CT RevitL Launch Or Is That Priced In?
Enovis (ENOV) recently launched CT-RevitL, a new veterinary PBM laser therapy system, which has contributed to a short-term rebound in its share price. Despite some analysts valuing the stock at $42.30, indicating a 36% undervaluation, concerns remain regarding integration challenges from acquisitions and potential delays in other tech launches like Arvis. The article suggests that investors should review the company's financial data to determine if the current price reflects its potential or if further upside exists.
Is Enovis (ENOV) Undervalued On Its CT RevitL Launch Or Is That Priced In?
Enovis (ENOV) recently launched its CT-RevitL veterinary PBM laser therapy system, which has contributed to short-term share price momentum. Despite a significant rebound, the company is still considered 36% undervalued with a fair value pegged at $42.30, contingent on strong execution in orthopedics and new technologies and successfully navigating integration challenges and potential tech launch delays.
Is Enovis (ENOV) Using CT-RevitL to Quietly Redefine Its Veterinary Innovation Strategy?
Enovis Corporation (ENOV) has launched CT-RevitL, a new veterinary laser therapy system, which could enhance its recurring-use product portfolio. While this product is promising, the company's immediate focus remains on integrating past acquisitions, improving margins, and demonstrating profitable growth, with its Q2 2026 earnings release being a key near-term catalyst. Investors should consider Enovis's overall financial health,
